PXS5505-MF101
30 Nov 2021
Trial Summary
This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis
Acronym:
PXS5505-MF101
ACTRN/NCT /ethics:
NCT04676529
Scientific title:
A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Sponsor / Cooperative group:
Pharmaxis
Trial & Patient Characteristics
| Cancer Type | Blood |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I, Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2021-02-18 |
| Anticipated End Date | 2022-06-22 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Stanley Cheung |
| Recruitment Status | Recruiting |